HPSE and plasma cell myeloma: Likewise, the heparanase inhibitor Roneparstat (formerly SST0001) in combination with a proteasome inhibitor (bortezomid) or melphalan was found to be an effective therapeutic strategy to inhibit disseminated tumor growth and overcome drug resistance in myeloma bearing mice [38].